FOR REDUCES HUNGER BY WORKING ON THE BRAINS APPETITE CENTER SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases
M.WangL
Ongoing trials, including phase III studies of semaglutide and emerging dual/triple agonists like tirzepatide, aim to provide further evidence on their efficacy
From a clinical perspective, this makes Allulose a promising low-calorie sweetener for people with diabetes, prediabetes, insulin resistance, or those simply looking to reduce added sugar intake without sacrificing taste
Key findings, including the potential protective effects of GLP-1RAs on schizophrenia, anxiety disorders, and autism, were consistently observed across multiple independent datasets, reinforcing the robustness and reproducibility of the results